Weight Loss at a Med Spa: GLP-1 Programs, Injections and Body Contouring

The first thing to sort out is what you are actually buying, because the categories do different jobs.

Losing weight means reducing total body mass, and the non-invasive fat-reduction devices med spas use do not do that.

What med spas sell as fat reduction does something else: it treats one small pocket of fat that has not responded to diet and exercise.

The American Academy of Dermatology (AAD) describes good candidates for non-invasive fat removal as people with a small bulge of fat that remains despite diet and exercise and whose weight is in the normal range for their height — and it says plainly that this is not a weight-loss method.

The cleared devices are built for that narrow job.

CoolSculpting Elite is FDA-cleared — 510(k) K233732, September 12, 2024, a clearance rather than an approval — for cold-assisted fat breakdown of the upper arm, bra fat, back fat, banana roll, thigh, abdomen and flanks in people with a BMI of 30 or less, and of the under-chin and under-jaw areas with a BMI up to 46.2.

Its clearance also says that, used under the chin, it can affect the appearance of lax submental tissue.

The AAD describes the results as subtle compared with liposuction — "pants a little looser" — and notes that fat cells destroyed do not come back, although the remaining fat cells in the area can still expand with weight gain.

Our coolsculpting guide covers how fat freezing works, what sessions cost and the risks.

Medical weight loss is the med spa category aimed at the scale itself: prescription programs built on GLP-1 medicines.

Two of the brand-name prescription medicines with weight-management indications are Wegovy (semaglutide) and Zepbound (tirzepatide).

The labels scope them tightly.

Wegovy is approved as an injection, with diet and activity, to reduce and maintain excess body weight in adults and children 12 and older with obesity and in adults with overweight plus a weight-related condition.

Zepbound is indicated, with diet and exercise, for chronic weight management in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.

What to weigh beyond the prescription itself — screening, labs, monthly price, telehealth or in-person visits — is its own topic: our medical weight loss guide covers it, and the drug-level detail lives in the semaglutide and tirzepatide guides.

The labels carry serious warnings.

Wegovy and Zepbound both carry a boxed warning for thyroid C-cell tumors, seen in rodents, with human relevance the labels say is unknown — and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

The labels also address pregnancy.

Wegovy's label says to discontinue when pregnancy is recognized, and to stop at least 2 months before a planned pregnancy because of semaglutide's long half-life.

Zepbound's label says it may cause fetal harm and should be stopped when pregnancy is recognized, and that it can reduce the effectiveness of oral birth control pills — the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.

Compounded versions of semaglutide and tirzepatide are also sold for weight loss — a market the FDA addresses directly with red-flag lists for GLP-1 sellers and for telehealth GLP-1 offers.

The FDA's position is blunt: compounded GLP-1 drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality, and should be used only when a patient's medical needs cannot be met by an FDA-approved drug.

The FDA also says the salt forms (semaglutide sodium, semaglutide acetate) are different active ingredients from the approved drugs and that it knows of no lawful basis for compounding with them, and that retatrutide and cagrilintide cannot be used in compounding under federal law.

For anyone who does receive a compounded injectable GLP-1, the FDA advises discarding a multi-dose vial within 28 days of first use, even if medication remains, and not using any injectable GLP-1 that arrives warm.

The compounding rules, and what to ask a clinic that still offers compounded vials, are covered in our compounded GLP-1s at med spas guide.

Weight-loss program menus at med spas also sell "lipo" injections — also called lipotropic or MIC injections — and vitamin B12 shots.

The FDA label behind injectable cyanocobalamin (vitamin B12) covers one use: vitamin B12 deficiency due to malabsorption, as in Addisonian (pernicious) anemia or after some gastrointestinal surgery.

Weight loss, fat burning and energy are not approved uses of the B12 injection, and "lipo" or lipotropic (MIC) injections are not FDA-approved for weight loss.

Beyond the deficiency use on the label, these injections carry no FDA-approved weight-loss role — so the question to ask a program that sells them is what the shot is for, specifically.

Once weight comes off, the question changes shape: what to do about what is left behind.

The American Society of Plastic Surgeons (ASPS) put numbers on the demand: in its 2025 survey, 82% of member plastic surgeons reported GLP-1-related consultation requests.

The most common body requests were tummy tucks (88%), breast surgery (87%), arm lifts (84%) and thigh lifts (80%).

ASPS's 2025 procedure statistics also show facial fat grafting up 39% to 34,117 cases — the largest percentage rise of any cosmetic surgery — alongside upper body lifts (+22%), arm lifts (+21%) and thigh lifts (+20%), growth ASPS links to GLP-1 weight loss.

Those are surgical procedures, decided case by case with a plastic surgeon.

The non-surgical med spa options address narrower problems: the fat-reduction devices described above work on small bulges within the cleared BMI limits, and skin tightening is its own conversation, taken up below.

Rapid weight loss can show up in the face and in the skin. "Ozempic face" is a popular-culture term, not a medical diagnosis, for the facial hollowing and skin laxity that can follow rapid weight loss.

Plastic surgeons describe the same changes clinically as facial volume loss and soft-tissue descent from reduced facial fat.

A 2025 imaging study of 20 patients on GLP-1 drugs, whose average weight loss was 11 kg, measured a median 9% decrease in midface volume — an average of 7% of midfacial volume per 10 kg of total weight loss, mainly in the superficial fat pads.

That is one small retrospective study, so read it as the mechanism, not as a personal prediction.

The skin is the harder part.

In a 2026 survey of 406 aesthetic clinicians, with co-authors from Allergan Aesthetics, midface volume loss, face and neck skin laxity and loose body skin were the changes most linked to GLP-1 weight loss, and those clinicians considered hyaluronic acid filler the best facial treatment for an average of 47% of patients — a survey of clinician opinion, not trial data.

ASPS's 2025 survey reported GLP-1-related facial consultation requests most often for facelifts (71%), neck lifts (64%) and eyelid surgery (37%).

An ASPS member surgeon quoted in the report said non-invasive and minimally invasive tightening technologies "still leave a lot to be desired" for widespread laxity after GLP-1 weight loss — one surgeon's stated opinion, not a study finding.

The non-surgical benchmark is modest: the AAD calls ablative laser resurfacing the most effective non-surgical procedure for tightening loose skin, and even that means 5 to 7 days at home and a higher risk of side effects such as scarring.

For surgery, ASPS describes good body lift candidates as people with significant soft-tissue looseness who are healthy, non-smoking, and have realistic goals and a committed healthy lifestyle.

No source we captured names a specific weight-loss amount or weight-stability period at which surgery is advised — that assessment belongs to a plastic surgeon.

Where each option fits — filler for volume, the tightening devices, surgical lifts — is mapped in our skin and body concerns hub, and the device choices are compared in our skin tightening guide.

GLP-1 drugs are prescription-only — the label is marked "Rx only" — and who may prescribe and supervise them at a med spa (a physician, an NP or a PA; whether your exam happens on site or by telehealth) is set by state law, not by the FDA label.

Injections raise the same kind of question.

AmSpa, the medical spa trade association, says injecting botulinum toxin is the practice of medicine — because it uses a prescription drug — so it must be done by a physician, an independent-practice NP or another licensed professional acting within their scope, under rules that vary by state.

For the prescription weight-loss drugs, the question to settle before you pay is simple: who is the prescriber, what is their license, and who examines you before a prescription is written?

Our guide to who can prescribe GLP-1s walks through the license types, the good-faith exam and what to ask a clinic's medical director, and med spa laws by state collects the supervision rules state by state.

Vetting matters more here than for a facial, because this category mixes prescription drugs with cosmetic devices.

The FDA's red flags for GLP-1 sellers are a usable checklist on their own:

• Claims that a compounded drug is the same as the FDA-approved drug.
• Prices that are too good to be true.
• No screening or prescription by a licensed doctor.
• No doctor available for questions.

If a clinic hands you a compounded injectable, the FDA's handling advice for patients applies: discard a multi-dose vial within 28 days of first use, and do not use any injectable GLP-1 that arrives warm.

Our guide to choosing a med spa covers the rest of the check — who the medical director is, who will actually treat you, and what a real consultation looks like — before you book a consultation with anyone local.